In clinical trials, a biomarker (S ) that is measured after randomization and is strongly associated with the true endpoint (T) can often provide information about T and hence the effect of a treatment (Z ) on T. A useful biomarker can be measured earlier than T and cost less than T. In this article,… Continue reading A shrinkage approach for estimating a treatment effect using intermediate biomarker data in clinical trials
Keyword: MHDA- 2012/04/05 06:00
Tests and expenditures in the initial evaluation of peripheral neuropathy
BACKGROUND: Peripheral neuropathy is a common disorder in which an extensive evaluation is often unrevealing. METHODS: We sought to define diagnostic practice patterns as an early step in identifying opportunities to improve efficiency of care. The 1996-2007 Health and Retirement Study Medicare claims-linked database was used to identify individuals with an incident diagnosis of peripheral… Continue reading Tests and expenditures in the initial evaluation of peripheral neuropathy